Comparative in vitro activity of plazomicin and older aminoglyosides against Enterobacterales isolates; prevalence of aminoglycoside modifying enzymes and 16S …
D Gür, U Hasdemir, A Çakar, İ Çavuşoğlu… - … and infectious disease, 2020 - Elsevier
Comparative in vitro activity of plazomicin and 4 older aminoglycosides was evaluated with
broth microdilution in 714 blood isolates from 14 hospitals in Turkey. Isolates included …
broth microdilution in 714 blood isolates from 14 hospitals in Turkey. Isolates included …
In vitro activity of plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions
M Castanheira, AP Davis, AW Serio, KM Krause… - … and Infectious Disease, 2019 - Elsevier
Aminoglycoside-nonsusceptible isolates of Escherichia coli, Klebsiella, Proteus, and
Enterobacter species (480/3675) from US hospitals collected during 2014–2015 were …
Enterobacter species (480/3675) from US hospitals collected during 2014–2015 were …
[PDF][PDF] Activity of plazomicin against Enterobacteriaceae isolates collected in the United States including isolates carrying aminoglycoside-modifying enzymes detected …
M Castanheira, LM Deshpande… - Open Forum …, 2017 - pdfs.semanticscholar.org
Methods. A total of 10,451 Enterobacteriaceae (ENT) consecutively collected from 84 United
States (US) medical centers and 250 carbapenem-resistant ENT (CRE) collected from 38 …
States (US) medical centers and 250 carbapenem-resistant ENT (CRE) collected from 38 …
Activity of Plazomicin Tested against Enterobacterales Isolates Collected from US Hospitals in 2016–2017: Effect of Different Breakpoint Criteria on Susceptibility …
ABSTRACT Plazomicin was active against 97.0% of 8,783 Enterobacterales isolates
collected in the United States (2016 and 2017), and only 6 isolates carried 16S rRNA …
collected in the United States (2016 and 2017), and only 6 isolates carried 16S rRNA …
Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly …
M Castanheira, LM Deshpande… - Journal of …, 2018 - academic.oup.com
Background Plazomicin is a next-generation aminoglycoside that was developed to
overcome common aminoglycoside-resistance mechanisms. Objectives We evaluated the …
overcome common aminoglycoside-resistance mechanisms. Objectives We evaluated the …
Impact of the recent clinical and Laboratory Standards Institute breakpoint changes on the Antimicrobial Spectrum of Aminoglycosides and the activity of Plazomicin …
HS Sader, RE Mendes, JH Kimbrough… - Open Forum …, 2023 - academic.oup.com
Abstract Background The Clinical and Laboratory Standards Institute (CLSI) lowered the
Enterobacterales-susceptible/-resistant breakpoints for amikacin in 2023 from≤ 16/≥ 64 …
Enterobacterales-susceptible/-resistant breakpoints for amikacin in 2023 from≤ 16/≥ 64 …
In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from US Hospitals and Comparative Activities of Aminoglycosides against …
M Castanheira, AP Davis, RE Mendes… - Antimicrobial Agents …, 2018 - Am Soc Microbiol
Plazomicin and comparator agents were tested by using the CLSI reference broth
microdilution method against 4,825 clinical isolates collected during 2014 and 2015 in 70 …
microdilution method against 4,825 clinical isolates collected during 2014 and 2015 in 70 …
In Vitro Activity of Plazomicin Compared to Amikacin, Gentamicin, and Tobramycin against Multidrug-Resistant Aerobic Gram-Negative Bacilli
WA Fleischmann… - Antimicrobial agents …, 2020 - Am Soc Microbiol
The worldwide spread of multidrug-resistant Enterobacterales is a serious threat to public
health. Here, we compared the MICs of plazomicin, amikacin, gentamicin, and tobramycin …
health. Here, we compared the MICs of plazomicin, amikacin, gentamicin, and tobramycin …
Plazomicin activity against 346 extended-spectrum-β-lactamase/AmpC-producing Escherichia coli urinary isolates in relation to aminoglycoside-modifying enzymes
MC López-Diaz, E Culebras… - Antimicrobial agents …, 2017 - Am Soc Microbiol
The activity of plazomicin and clinically relevant aminoglycosides was tested against 346
extended-spectrum-β-lactamase/AmpC-producing Escherichia coli urinary isolates, and the …
extended-spectrum-β-lactamase/AmpC-producing Escherichia coli urinary isolates, and the …
In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the …
A Walkty, H Adam, M Baxter, A Denisuik… - Antimicrobial agents …, 2014 - Am Soc Microbiol
Plazomicin is a next-generation aminoglycoside that is not affected by most clinically
relevant aminoglycoside-modifying enzymes. The in vitro activities of plazomicin and …
relevant aminoglycoside-modifying enzymes. The in vitro activities of plazomicin and …